Literature DB >> 1458554

Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.

V Gandhi1, W Plunkett.   

Abstract

Exponentially growing K562 cells incubated with 1-beta-D-arabinofuranosylcytosine (ara-C) accumulate ara-C triphosphate (ara-CTP) at a higher rate and to a greater concentration after pretreatment with 9-beta-D-arabinofuranosyl-2-fluoroadenine (F-ara-A) than do cells treated with ara-C alone. Potentiation of ara-C metabolism is due in part to an indirect effect of F-ara-A triphosphate (F-ara-ATP)-mediated reduction in deoxynucleotide pools and consequent activation of deoxycytidine kinase. Because the levels of deoxynucleotide pools and the activity of deoxycytidine kinase are cell cycle-specific, we investigated the effect of cell cycle phases on the accumulation of ara-CTP and the influence of F-ara-A pretreatment on such accumulation. Exponentially growing K562 cells were fractionated into G1, S, and G2+M phase-enriched subpopulations (each enriched by > 60%) by centrifugal elutriation. The rate of ara-CTP accumulation was 22, 25, and 14 microM/h and the rate of F-ara-ATP accumulation was 38, 47, and 33 microM/h in the G1, S, and G2+M subpopulations, respectively. The rate of elimination of arabinosyl triphosphates was similar among the different phases of the cell cycle. After pretreatment with F-ara-A, the rate of ara-CTP accumulation in the G1, S, and G2+M phase-enriched subpopulations was 43, 37, and 26 microM/h, indicating a 1.7-, 1.5-, and 1.9-fold increase, respectively. These results suggest that a combination of F-ara-A and ara-C may effectively potentiate ara-CTP accumulation in all phases of the cell cycle. This observation is consistent with the results of studies on the modulation of ara-C metabolism by F-ara-A in lymphocytes and leukemia blasts obtained from patients with chronic lymphocytic leukemia and acute myelogenous leukemia, respectively.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1458554     DOI: 10.1007/bf00695988

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  41 in total

1.  NUCLEOTIDE SEQUENCE ANALYSIS OF POLYRIBONUCLEOTIDES BY MEANS OF PERIODATE OXIDATION FOLLOWED BY CLEAVAGE WITH AN AMINE.

Authors:  H C NEU; L A HEPPEL
Journal:  J Biol Chem       Date:  1964-09       Impact factor: 5.157

2.  Deoxycytidine kinase, thymidine kinase and cytidine deaminase and the formation of Ara-CTP in leukemic cells in different phases of the cell cycle.

Authors:  D J Richel; L P Colly; M W Arentsen-Honders; C W Starrenburg; R Willemze
Journal:  Leuk Res       Date:  1990       Impact factor: 3.156

3.  Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells.

Authors:  V Gandhi; W Plunkett
Journal:  Cancer Res       Date:  1988-01-15       Impact factor: 12.701

4.  Interaction of arabinosyl nucleotides in K562 human leukemia cells.

Authors:  V Gandhi; W Plunkett
Journal:  Biochem Pharmacol       Date:  1989-10-15       Impact factor: 5.858

5.  Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C.

Authors:  W Plunkett; J O Liliemark; E Estey; M J Keating
Journal:  Semin Oncol       Date:  1987-06       Impact factor: 4.929

6.  Deoxycytidine kinase. I. Distribution in normal and neoplastic tissues and interrelationships of deoxycytidine and 1-beta-D-arabinofuranosylcytosine phosphorylation.

Authors:  J P Durham; D H Ives
Journal:  Mol Pharmacol       Date:  1969-07       Impact factor: 4.436

7.  Comparison of the toxicity and metabolism of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine in human lymphoblastoid cells.

Authors:  W Plunkett; S Chubb; L Alexander; J A Montgomery
Journal:  Cancer Res       Date:  1980-07       Impact factor: 12.701

8.  In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells.

Authors:  W C Tseng; D Derse; Y C Cheng; R W Brockman; L L Bennett
Journal:  Mol Pharmacol       Date:  1982-03       Impact factor: 4.436

9.  Improved prospects for long-term survival in adults with acute myelogenous leukemia.

Authors:  M J Keating; K B McCredie; G P Bodey; T L Smith; E Gehan; E J Freireich
Journal:  JAMA       Date:  1982-11-19       Impact factor: 56.272

10.  Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy.

Authors:  W Plunkett; V Hug; M J Keating; S Chubb
Journal:  Cancer Res       Date:  1980-03       Impact factor: 12.701

View more
  3 in total

Review 1.  The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signalling.

Authors:  Wilhelm Engström; Philippa Darbre; Staffan Eriksson; Linda Gulliver; Tove Hultman; Michalis V Karamouzis; James E Klaunig; Rekha Mehta; Kim Moorwood; Thomas Sanderson; Hideko Sone; Pankaj Vadgama; Gerard Wagemaker; Andrew Ward; Neetu Singh; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Anna Maria Colacci; Monica Vaccari; Chiara Mondello; A Ivana Scovassi; Jayadev Raju; Roslida A Hamid; Lorenzo Memeo; Stefano Forte; Rabindra Roy; Jordan Woodrick; Hosni K Salem; Elizabeth P Ryan; Dustin G Brown; William H Bisson
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

2.  Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG.

Authors:  M Fiegl; M Unterhalt; W Kern; J Braess; K Spiekermann; P Staib; A Grüneisen; B Wörmann; D Schöndube; H Serve; A Reichle; M Hentrich; X Schiel; C Sauerland; A Heinecke; C Rieger; D Beelen; W E Berdel; T Büchner; W Hiddemann
Journal:  Leukemia       Date:  2013-10-22       Impact factor: 11.528

Review 3.  Genetic factors influencing cytarabine therapy.

Authors:  Jatinder K Lamba
Journal:  Pharmacogenomics       Date:  2009-10       Impact factor: 2.533

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.